Results 251 to 260 of about 871,553 (293)

Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection. [PDF]

JCI Insight
Happe M, Lynch RM, Fichtenbaum CJ, Heath SL, Koletar SL, Landovitz RJ, Presti RM, Santana-Bagur JL, Tressler RL, Holman LA, Novik L, Roa JC, Rothwell RS, Strom L, Wang J, Hu Z, Conan-Cibotti M, Bhatnagar AM, Dwyer B, Ko SH, Belinky F, Namboodiri AM, Pandey JP, Carroll R, Basappa M, Serebryannyy L, Narpala SR, Lin BC, McDermott AB, Boritz EA, Capparelli EV, Coates EE, Koup RA, Ledgerwood JE, Mascola JR, Chen GL, Tebas P, VRC 607/A5378 Study Team.   +37 more
europepmc   +1 more source

Cost-effectiveness of broadly neutralizing antibodies for HIV prophylaxis for infants born in settings with high HIV burdens. [PDF]

PLoS One
Alba C, Malhotra S, Horsfall S, Barnhart ME, Bekker A, Chapman K, Cunningham CK, Fast PE, Fouda GG, Freedberg KA, Goga A, Ghazaryan LR, Leroy V, Mann C, McCluskey MM, McFarland EJ, Muturi-Kioi V, Permar SR, Shapiro R, Sok D, Stranix-Chibanda L, Weinstein MC, Ciaranello AL, Dugdale CM.   +23 more
europepmc   +1 more source

Isolation and escape mapping of broadly neutralizing antibodies against emerging delta-coronaviruses. [PDF]

Immunity
Rexhepaj M, Asarnow D, Perruzza L, Park YJ, Guarino B, Mccallum M, Culap K, Saliba C, Leoni G, Balmelli A, Yoshiyama CN, Dickinson MS, Quispe J, Brown JT, Tortorici MA, Sprouse KR, Taylor AL, Corti D, Starr TN, Benigni F, Veesler D.   +20 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Delivery platforms for broadly neutralizing antibodies

Current Opinion in HIV and AIDS, 2023
Purpose of review Passive administration of broadly neutralizing antibodies (bNAbs) is being evaluated as a therapeutic approach to prevent or treat HIV infections. However, a number of challenges face the widespread implementation of passive transfer for HIV. To reduce the need of recurrent administrations of bNAbs, gene-based
Lok R, Joshi, Nicolás M S, Gálvez, Sukanya, Ghosh, David B, Weiner, Alejandro B, Balazs   +4 more
openaire   +2 more sources

Broadly neutralizing antibodies against influenza viruses [PDF]

Antiviral Research, 2013
Despite available antivirals and vaccines, influenza continues to be a major cause of mortality worldwide. Vaccination generally induces an effective, but strain-specific antibody response. As the virus continually evolves, new vaccines have to be administered almost annually when a novel strain becomes dominant.
Ian Andrew Wilson, Nick S Laursen
exaly   +3 more sources

Broadly neutralizing antibodies in HIV-1 treatment and prevention

Therapeutic Advances in Vaccines and Immunotherapy, 2018
Antibodies that naturally develop in some individuals infected with human immunodeficiency virus 1 (HIV-1) and are capable of broadly neutralizing diverse strains of HIV-1 are useful for two applications: they can inform the rational design of vaccine ...
Jayanta Bhattacharya, Suprit Deshpande, Rajesh Kumar   +2 more
exaly   +2 more sources

Broadly Neutralizing Antibodies for HIV Prevention

Annual Review of Medicine, 2020
In the last decade, over a dozen potent broadly neutralizing antibodies (bnAbs) to several HIV envelope protein epitopes have been identified, and their in vitro neutralization profiles have been defined. Many have demonstrated prevention efficacy in preclinical trials and favorable safety and pharmacokinetic profiles in early human clinical trials ...
Shelly T, Karuna, Lawrence, Corey
openaire   +2 more sources

Discovery of O-Linked Carbohydrate on HIV-1 Envelope and Its Role in Shielding against One Category of Broadly Neutralizing Antibodies

Cell Reports, 2020
Summary: Approximately 50% of the mass of the Envelope (Env) glycoprotein surface subunit (gp120) of human immunodeficiency virus type 1 (HIV-1) is composed of N-linked carbohydrate. Until now, the dogma has been that HIV-1 lacks O-linked carbohydrate on
Michael S Seaman, Ronald C Desrosiers, Aristotelis Antonopoulos   +2 more
exaly   +3 more sources

In vivo protection by broadly neutralizing HIV antibodies

Trends in Microbiology, 2014
Passive immunization studies, including a recent one by Pegu et al., have repeatedly shown that HIV-specific broadly neutralizing antibodies (bnAbs) protect rhesus macaques from HIV acquisition. In vitro neutralization potency and in vivo protection correlate very strongly, supporting the quest for an HIV vaccine that induces potent bnAbs.
Marit J. van Gils, Rogier W. Sanders
openaire   +2 more sources

A recipe for inducing broadly neutralizing antibodies

Nature Reviews Immunology, 2016
An immune profile associated with the production of broadly neutralizing antibodies is identified in HIV-1-infected individuals.
openaire   +2 more sources